A breath test for malignant mesothelioma using an electronic nose

European Respiratory Journal

Volumn 40, Issue 2, 2012, Pages 448-454

  Chapman, Eleanor A ^a   Thomas, Paul S ^a   Stone, Emily ^b   Lewis, Craig ^c   Yates, Deborah H ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Asbestos; Biomarkers; Breath testing; Electronic nose; Mesothelioma; Volatile organic compounds

Indexed keywords

VOLATILE ORGANIC COMPOUND;

AGED; ANALYTICAL EQUIPMENT; ARTICLE; ASBESTOSIS; AUTOANALYZER; BREATH ANALYSIS; CARBON POLYMER ARRAY ELECTRIC NOSE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; PLEURA DISEASE; PLEURA MESOTHELIOMA; PORTABLE EQUIPMENT; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REPRODUCIBILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

AGED; ASBESTOS; BIOLOGICAL MARKERS; BREATH TESTS; CARBON; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; LUNG DISEASES; MALE; MESOTHELIOMA; MIDDLE AGED; POLYMERS; PRINCIPAL COMPONENT ANALYSIS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPIROMETRY; VOLATILE ORGANIC COMPOUNDS;

EID: 84864766479     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00040911     Document Type: Article

References (39)

1. Park EK, Hannaford Turner K, Hyland RA, et al. Asbestos related occupational lung diseases in NSW, Australia, and potential exposure of the general population. Ind Health 2008; 46: 535-540.
2. World Health Organization. World Health Assembly Resolution 58.22 Elimination of Asbestos-Related Disease. Geneva, WHO, 2006.
3. Clements M, Berry G, Shi J, et al. Projected mesothelioma incidence in men in New South Wales, Australia. Occup Environ Med 2007; 64: 747-752. (Pubitemid 350044088)
4. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax 1999; 54: 638-652. (Pubitemid 29296687)
5. Chapman EA, Thomas PS, Yates DH. Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res 2010; 4: 034001.
6. Hyland R, Ware S, Johnson A, et al. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scn J Work Environ Health 2007; 33: 286-292. (Pubitemid 47408254)
7. American Thoracic Society, Medical Section of the American Lung Association: the diagnosis of non-malignant diseases related to asbestos. Am Rev Respir Dis 1986; 134: 363-368.
8. Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009; 21: 97-104.
9. Tossavainen A. Asbestos, asbestosis and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health Perspect 1997; 23: 311-316. (Pubitemid 27429697)
10. Chow S, Campbell C, Sandrini A, et al. Exhaled breath condensate biomarkers in asbestos related lung disorders. Respir Med 2009; 103: 1091-1097.
11. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-1160. (Pubitemid 43726897)
12. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein - a blood test for mesothelioma. Lung Cancer 2005; 49: Suppl. 1, S109-S111. (Pubitemid 40798859)
13. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85: 265-272. (Pubitemid 350265805)
14. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with mesothelioma. J Thorac Oncol 2008; 3: 851-857.
15. Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009; 64: 166-170.
16. Horvath I, Lázár Z, Gyulai N, et al. Exhaled biomarkers in lung cancer. Eur Respir J 2009; 34: 261-275.
17. Phillips M, Altorki N, Austin JHM. Detection of lung cancer using weighted digitial analysis of breath biomarkers. Clin Chim Acta 2008; 393: 76-84.
18. Wehinger A, Schmid A, Mechtcheriakov S, et al. Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas. Int J Mass Spec 2007; 265: 49-59.
19. Mazzone PJ, Hammel J, Dweik RA, et al. Lung cancer diagnosis by the analysis of exhaled breath with a colorimetric sensor array. Thorax 2007; 62: 565-568. (Pubitemid 47056880)
20. Phillips M, Altorki N, Austin JHM, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 2007; 3: 95-109. (Pubitemid 47103811)
21. McCulloch M, Jezierski T, Broffman M, et al. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Intergr Cancer Ther 2006; 5: 30-39. (Pubitemid 43260792)
22. Cheng ZJ, Warwick G, Yates DH, et al. An electronic nose in the discrimination of breath from smokers and non-smokers: a model for toxin exposure. J Breath Res 2009; 3: 36-41.
23. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62: Suppl. 2, ii1-ii19.
24. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
25. Cotes JE, Chinn DJ, Quanjer PH. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests European Community for Steel and Coal. Eur Respir J 1993; 6: Suppl. 16, 41-52.
26. Savitsky A, Golay MJE. Smoothing and differentiation of data by simplified least square procedures. Anal Chem 1964; 36: 1627-1639.
27. Wold S, Ebensen K, Geladi P. Principal component analysis. Chemom Intell Lab Syst 1987; 2: 37-52.
28. Dragonieri S, van der Schee MP, Massaro T, et al. An electronic nose distinguishes exhaled breath of patients with malignant pleural mesothelioma from controls. Lung Cancer 2012; 75: 326-331.
29. Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009; 180: 1076-1082.
30. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010; 8: 740-801.
31. Agarwala M, Brahmandaya G, Chmielewskib GW, et al. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 2010; 68: 398-402.
32. Phillips M, Cantaneo R, Cummin A, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003; 123: 2115-2123. (Pubitemid 36706741)
33. Phillips M, Greenberg J, Awad J. Metabolic and environmental origins of volatile organic compounds in breath. J Clin Pathol 1994; 47: 1052-1053.
34. Phillips M, Gleeson K, Hughes J, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999; 535: 1930-1933. (Pubitemid 29255706)
35. Machado R, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analysese of exhaled breath. Am J Respir Crit Care Med 2005; 171: 1286-1291. (Pubitemid 40740737)
36. Dragonieri S, Schot R, Mertens BJA, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007; 120: 856-862. (Pubitemid 47542280)
37. de Gennaro G, Dragonieri S, Longobardi F, et al. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure. Anal Bioanal Chem 2010; 398: 3043-3050.
38. Moser B, Bodrogi F, Eibl G, et al. Mass spectrometric profile of exhaled breath: field study by PTR-MS. Respir Physiol Neurobiol 2005; 145: 295-300. (Pubitemid 40215660)
39. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008; 178: 832-837.